Regulatory Pressure Mounts for Telehealth Firm Hims & Hers Following FDA Warning

The telehealth sector faces renewed scrutiny as Hims & Hers Health finds itself in the crosshairs of US regulators. A formal warning letter from the Food and Drug Administration (FDA), issued on September 9, has cast a shadow over the company’s advertising practices for its weight-loss medications, sending its shares lower and prompting market analysts to reassess their outlook.

FDA Crackdown on Compounded Drug Claims

At the heart of the regulatory action are assertions made by Hims & Hers regarding its compounded semaglutide products. The FDA’s letter charges the company with making “false and misleading” claims by suggesting these offerings contain “the same active ingredient as Ozempic and Wegovy” and utilize “clinically proven ingredients.”

The agency delivered an unambiguous message: compounded medications lack FDA approval. The letter explicitly states that the company’s promotional materials wrongly imply its products are identical to federally approved drugs.

This warning was not an isolated event. It formed part of a broader initiative by the regulatory body, which dispatched over 100 similar communications to various pharmaceutical and telehealth companies on the same day.

Business Model Faces Critical Test

Hims & Hers had successfully capitalized on a market opportunity by offering more affordable alternatives to blockbuster weight-loss drugs. This strategy leveraged a regulatory gray area that permitted pharmacies to legally produce compounded versions during periods of shortage for the branded medications.

However, the landscape shifted when the FDA declared the drug shortage over in February 2025. Since that time, the company has relied on a regulatory exception that allows for “personalized” dosages to continue its operations.

In response to the FDA’s challenge, the company struck a conciliatory tone. A statement expressed eagerness to “engage in a dialogue with the FDA” and highlighted that its existing materials already note that compounded treatments are not subject to FDA review or approval.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Market Reaction and Analyst Sentiment

The financial markets reacted promptly to the news. The Motley Fool captured the shifting mood on September 24 with an article titled “I’m Downgrading Hims & Hers Stock,” pointing directly to the heightened regulatory risks.

Interestingly, while Hims & Hers faced pressure, the shares of original drug manufacturers Eli Lilly and Novo Nordisk advanced by 2.8% and 2.1% respectively, despite also receiving FDA letters. This suggests investor speculation that reduced competition from compounded alternatives could benefit the established pharmaceutical giants.

Strong Operational Performance Amid Uncertainty

Despite the regulatory headwinds, the company’s underlying business metrics remain robust. For the second quarter of 2025, revenue surged 73% to $544.8 million. Its subscriber base expanded significantly, growing 31% year-over-year to surpass 2.4 million users.

Management has reaffirmed its full-year revenue guidance of $2.3 to $2.4 billion. Looking further ahead, the company is targeting annual revenue of at least $6.5 billion by 2030.

A Tight Deadline and High Stakes

The company now operates under a strict 15-business-day deadline to formally respond to the FDA. It must either demonstrate corrective actions to achieve compliance or provide evidence that its products do not violate federal statutes. An inadequate response could trigger legal consequences, including potential product seizures.

All eyes will be on the next quarterly report, expected in November, for management’s commentary on the operational impact of these regulatory developments. The central question for investors is whether the “personalized dosage” pathway provides a durable, legitimate foundation for Hims & Hers to sustain its weight-loss medication business.